BMAC – Biopharmaceutical Manufacturer's Advisory Council
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
Pfizer Inc. today announced the extension of the company’s highly automated Active Pharmaceutical Ingredient (API) manufacturing facility in Tuas Biomedical Park, Singapore. The official opening ceremony was graced by Singapore’s Deputy Prime Minister and Minister for Trade and Industry Mr. Gan Kim Yong.
When he was a child, Mr Shaji Alias watched a family member struggle with asthma and saw the difference that one of GSK’s medicines made. Little did he know that he would one day end up working for the global biopharma company.
Every parent of a newborn knows the toll of sleepless nights, and Mr Lam Wain Sion is no exception. However, thanks to the 16 weeks of paid parental leave he was entitled to as an employee of Swiss pharmaceutical company Novartis, he could help his wife with diaper changes and night feeds without worrying about turning up at work sleep-deprived.
The Biologics Pharma Innovation Programme Singapore (BioPIPS) consortium has been expanded with the addition of global immunotherapy company, BioNTech. The company joins global pharmaceutical companies GSK and Sanofi alongside Singapore’s research organisations and institutes of higher learning Agency for Science, Technology and Research (A*STAR), Nanyang Technological University, Singapore (NTU) and its innovation and enterprise company, NTUitive, National University of Singapore (NUS), and Singapore Institute of Technology (SIT).
Novartis today announced it broke ground for the expansion of its biopharmaceutical manufacturing plant in Singapore. The US$256 million investment will facilitate Novartis in deploying digital and automation solutions to enhance manufacturing productivity, improve operational efficiency, and upskill the workforce. The expanded site will focus on manufacturing therapeutic antibody drugs to deliver breakthrough treatments to patients globally.
AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network.
Roche today proudly commemorates its 50th anniversary of operations in Singapore. This milestone is being marked with a celebratory event attended by Mr. Ong Ye Kung, Minister for Health of Singapore and Dr. Thomas Schinecker, CEO of the Roche Group.
Our vaccines facility at Tuas is a key manufacturing site within our global network supplying the active ingredients used to make multiple paediatric vaccines.
Thermo Fisher Scientific, the world leader in serving science, has opened a new sterile drug facility in Singapore that will better enable customers to deliver new medicines and vaccines in the Asia-Pacific market. The new facility also marks a significant milestone and investment in pandemic preparedness for Singapore, which is fast emerging as a biomedical hub in the Asia-Pacific region.
First Positive Energy Building in Takeda’s Global Manufacturing Network and Singapore’s Pharmaceutical Industry